AMMECR1L: A Promising Drug Target and Biomarker for ALS-Like Diseases

Target Name: AMMECR1L

NCBI ID: G83607

AMMECR1L

AMMECR1L: A Promising Drug Target and Biomarker for ALS-Like Diseases

Introduction

Amnic ```am_normalize0
AMMECR1L, a protein that belongs to the Amazonia mining machine (AMM) family, is a unique protein that has caught the attention of researchers due to its unique structure and biological function. Recently, studies have identified AMMECR1L as a potential drug target and biomarker for a variety of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS).

AMMECR1L: Structure and Function

AMMECR1L is a 21-kDa protein that is expressed in various tissues and cells in the brain, including neurons, glial cells, and microglia. The protein has a unique structure that consists of a long N-terminus, a middle transmembrane region, and an C-terminus. The N-terminus of AMMECR1L contains a putative N-methyltransferase domain, which is known to play a role in the regulation of protein stability and localization.

The middle transmembrane region of AMMECR1L contains a unique feature that is characteristic of the AMM family of proteins. This region contains a putative transmembrane domain, which is involved in the formation of a complex with other proteins and is thought to play a role in the regulation of intracellular signaling pathways.

The C-terminus of AMMECR1L contains a series of conserved hydrophobic residues that are involved in the formation of a disulfide bond, which is a hallmark of proteins that contain cysteine 鈥嬧?媟esidues. This disulfide bond is important for the stability of the protein and is likely involved in its localization to specific cellular structures.

AMMECR1L in Neurodegenerative Diseases

Several studies have identified AMMECR1L as a potential drug target and biomarker for neurodegenerative diseases, including ALS. AlS is a progressive neurodegenerative disease that is characterized by the progressive loss of motor neurons and is often associated with the accumulation of neurofibrillary tangles and neuroglial cells in the brain.

Studies have shown that AMMECR1L is expressed in the brains of individuals with ALS and that the levels of the protein are decreased in the brains of individuals with the disease compared to healthy controls. Additionally, studies have shown that AMMECR1L is involved in the regulation of the neurotransmitter glutamate, which is a well-known neurotransmitter that is involved in the regulation of neural activity and is thought to play a role in the pathophysiology of ALS.

Furthermore, studies have also shown that AMMECR1L is involved in the regulation of the protein huntingtin, which is a protein that is known to play a role in the regulation of neural activity and is thought to be involved in the development of ALS-like diseases.

Drug Targeting and Biomarker Potential

The unique structure and function of AMMECR1L make it an attractive drug target and biomarker for neurodegenerative diseases. Studies have shown that AMMECR1L can be targeted by small molecules, such as inhibitors of the N-methyltransferase domain, which have been shown to be involved in the regulation of protein stability and localization.

In addition, the disulfide bond in the C-terminus of AMMECR1L is a potential target for drug targeting, as drugs that can modify the disulfide bond have been shown to be effective in the treatment of ALS-like diseases.

Biomarker Potential

The unique structure and function of AMMECR1L make it an attractive candidate for use as a biomarker for neurodegenerative diseases. Studies have shown that the levels of AMMECR1L are decreased in the brains of individuals with ALS compared to healthy controls, which suggests that

Protein Name: AMMECR1 Like

The "AMMECR1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AMMECR1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets